In ovarian cancer, the invasiveness of CD133(+) CSCs is enhanced by the chemokine CCL5, which activates CCR3 and CCR5 expressed by the cells to increase matrix metalloproteinase (MMP) 9 secretion [184]. The gene discussed is CCL5; the disease is ovarian cancer.